Since GLP-1R agonists are already approved for the treatment of type II diabetes and obesity due to its effectiveness in reducing food reward and craving, GLP-1 has become an attractive candidate for the treatment of substance use disorders including AUD (van Bloemendaal et al., 2014). The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.